The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes.

Roselle A Herring,Fariba Shojaee-Moradie,Mary Stevenage,Iain Parsons,Nicola Jackson,Jeewaka Mendis,Benita Middleton,A Margot Umpleby,Barbara A Fielding,Melanie Davies,David L Russell-Jones

Diabetes care（2022）

引用 5|浏览25

暂无评分

摘要

The increase in ketone enrichment from the ingested palmitic acid tracer suggests that meal-derived fatty acids contribute to the increase in ketones during treatment with dapagliflozin. The increase in BOHB concentration with dapagliflozin occurred with only minimal changes in plasma NEFA concentration and no change in lipolysis. This finding suggests a metabolic switch to increase ketogenesis within the liver.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要